Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. 1 Results ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for nemolizumab to treat moderate-to-severe prurigo nodularis in adults and moderate-to-severe atopic ...

Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest among inflammatory skin diseases. With this ...

Dupilumab shows significant benefits in prurigo nodularis severity and healing outcomes. Learn more about the latest Phase III trial findings.

The European Commission has approved nemolizumab (Nemluvio) for subcutaneous use in treating moderate to severe atopic dermatitis (AD) in patients aged ≥ 12 years and moderate to severe prurigo ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Currently, there are no approved topicals for the ...

Please provide your email address to receive an email when new articles are posted on . By week 100, 90% of participants achieved a 4-point or higher improvement in itch and 70% experienced an ...

Nemluvio was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with prurigo nodularis, and patients 12 years and older with moderate-to-severe atopic dermatitis, in ...

Nemluvio demonstrated long-term improvements in itch intensity, skin lesions and quality of life The OLYMPIA LTE study was designed to assess the safety and efficacy of Nemluvio in patients with ...

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226796734/en/ “Prurigo nodularis is not only ...

The OLYMPIA LTE study was designed to assess the safety and efficacy of Nemluvio in patients with prurigo nodularis up to four years and included 508 patients from the phase II trial and the OLYMPIA 1 ...